Literature DB >> 2387252

Alterations in thyroid status modulate apolipoprotein, hepatic triglyceride lipase, and low density lipoprotein receptor in rats.

B Staels1, A Van Tol, L Chan, H Will, G Verhoeven, J Auwerx.   

Abstract

The influence of altered thyroid state is investigated on plasma apolipoprotein-A-I (apo-A-I), apo-B, and apo-E levels and on apo-A-I, apo-A-II, apo-B, apo-E, hepatic triglyceride lipase (HTGL), and low density lipoprotein (LDL) receptor mRNA levels in rat liver and intestine. Plasma total cholesterol and triglycerides are unchanged in hyperthyroid rats. Liver apo-A-I mRNA levels increase 3-fold, whereas intestinal apo-A-I mRNA levels remain constant. Plasma apo-A-I levels almost double after L-T4. Liver apo-B and apo-E and intestinal apo-B mRNA levels are not influenced by L-T4, but plasma apo-B and apo-E decrease significantly. In the liver, apo-A-II mRNA levels decrease, whereas LDL receptor mRNA levels increase more than 50%. HTGL mRNA is not influenced by L-T4. N-Propyl-thiouracil-induced hypothyroidism does not influence plasma triglycerides, but plasma cholesterol levels nearly double. Liver and intestinal apo-A-I mRNA levels and plasma apo-A-I concentrations remain constant after propylthiouracil treatment. Accompanying the increase in plasma apo-B, liver and intestinal apo-B mRNA concentrations rise by approximately 100% and 40%, respectively. Plasma apo-E increases nearly 2-fold, but liver, apo-A-II mRNA rises, whereas HTGL and LDL receptor mRNA levels decrease 20% and nearly 50%, respectively. In conclusion, thyroid hormones regulate rat apo-A-I and apo-A-II gene expression in opposite directions. Furthermore, the LDL receptor is regulated at the mRNA level, whereas HTGL gene expression is relatively resistant to alterations in thyroid status.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2387252     DOI: 10.1210/endo-127-3-1144

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  20 in total

1.  The thyromimetic T-0681 protects from atherosclerosis.

Authors:  Ivan Tancevski; Andreas Wehinger; Egon Demetz; Julia Hoefer; Philipp Eller; Eva Huber; Ursula Stanzl; Kristina Duwensee; Kristina Auer; Wilfried Schgoer; Volker Kuhn; Catherine Fievet; Frans Stellaard; Mats Rudling; Bernhard Foeger; Josef R Patsch; Andreas Ritsch
Journal:  J Lipid Res       Date:  2008-12-22       Impact factor: 5.922

2.  Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis.

Authors:  G P Hayhurst; Y H Lee; G Lambert; J M Ward; F J Gonzalez
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

Review 3.  Next-generation gene discovery for variants of large impact on lipid traits.

Authors:  Elisabeth Rosenthal; Elizabeth Blue; Gail P Jarvik
Journal:  Curr Opin Lipidol       Date:  2015-04       Impact factor: 4.776

4.  Effects of hypothyroidism and high-fat feeding on mRNA concentrations for the low-density-lipoprotein receptor and on acyl-CoA:cholesterol acyltransferase activities in rat liver.

Authors:  A M Salter; R Hayashi; M al-Seeni; N F Brown; J Bruce; O Sorensen; E A Atkinson; B Middleton; R C Bleackley; D N Brindley
Journal:  Biochem J       Date:  1991-06-15       Impact factor: 3.857

5.  The proximal element of the human apolipoprotein A-II promoter increases the enhancer activity of the distal region.

Authors:  J M Lacorte; E Fourniat; D Pastier; J Chambaz; A Ribeiro; P Cardot
Journal:  Biochem J       Date:  1996-09-01       Impact factor: 3.857

6.  Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys.

Authors:  B R Ito; B-H Zhang; E E Cable; X Song; J M Fujitaki; D A MacKenna; C E Wilker; B Chi; P D van Poelje; D L Linemeyer; M D Erion
Journal:  Br J Pharmacol       Date:  2009-01-22       Impact factor: 8.739

Review 7.  The resurgence of thyromimetics as lipid-modifying agents.

Authors:  Ivan Tancevski; Philipp Eller; Josef R Patsch; Andreas Ritsch
Journal:  Curr Opin Investig Drugs       Date:  2009-09

8.  Increased macrophage colony-stimulating factor levels in patients with Graves' disease.

Authors:  Eriko Morishita; Akiko Sekiya; Tomoe Hayashi; Yasuko Kadohira; Mio Maekawa; Masahide Yamazaki; Hidesaku Asakura; Shinji Nakao; Shigeki Ohtake
Journal:  Int J Hematol       Date:  2008-08-27       Impact factor: 2.490

9.  Decreased expression of hepatic low-density lipoprotein receptor-related protein 1 in hypothyroidism: a novel mechanism of atherogenic dyslipidemia in hypothyroidism.

Authors:  Jae Hoon Moon; Hyung Jun Kim; Hyun Min Kim; Sung Hee Choi; Soo Lim; Young Joo Park; Hak Chul Jang; Bong Soo Cha
Journal:  Thyroid       Date:  2013-08-28       Impact factor: 6.568

10.  Evaluation of acute physiological and molecular alterations in surgically developed hypothyroid Wistar rats.

Authors:  Maulik Patel; Vinay Mishra; Vaibhavi Pawar; Ramchandran Ranvir; Rajesh Sundar; Rajas Dabhi
Journal:  J Pharmacol Pharmacother       Date:  2013-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.